Theravance Biopharma will lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Theravance Biopharma will lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.